Clinical Trial Update: A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis [Phase 4]

View source ↗

Summary

Phase 4 trial assessing efalizumab plus UVB for moderate to severe plaque psoriasis has completed; the update covers safety and efficacy outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Raptiva (efalizumab)

Snippet

Sponsor: Derm Research, PLLC | Conditions: Plaque Psoriasis | Phase 4 | Status: COMPLETED